UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
BUENA, N.J., May 01, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43rd Annual Health Care Conference. The Conference is taking place May 8-9, 2018 at the Intercontinental Hotel, Boston.
Damian Finio, Chief Financial Officer of Teligent, Inc., will present on Tuesday, May 8th at 12:50 p.m. ET.
The presentation will be webcast and accessible online via the investors section of the Company's website at www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
